Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling

Oncogene

Volumn 33, Issue 20, 2014, Pages 2620-2628

  Devine, D J ^a   Rostas, J W ^a,b   Metge, B J ^b   Das, S ^b   Mulekar, M S ^a   Tucker, J A ^b   Grizzle, W E ^b   Buchsbaum, D J ^c   Shevde, L A ^b   Samant, R S ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

breast cancer; epithelialmesenchymal transition; N Myc interactor; SMAD

Indexed keywords

MYC PROTEIN; N MYC INTERACTOR; SMAD PROTEIN; SMAD7 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BASEMENT MEMBRANE; BREAST CELL; BREAST METASTASIS; CANCER PATIENT; CARCINOGENESIS; CELL GROWTH; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYME CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION;

CELL LINE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE SILENCING; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84901190319     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.215     Document Type: Article

References (82)

1. Price JE. The biology of metastatic breast cancer. Cancer 1990; 66: 1313-1320. (Pubitemid 20307944
2. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15: 117-134
3. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Canc Metastasis Rev 2009; 28: 15-33
4. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982; 95: 333-339
5. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417-1419
6. Thiery JP. Epithelial-mesenchymal transitions in Development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746. (Pubitemid 37487967
7. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981
8. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003; 5: 101-106. (Pubitemid 36348104
9. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-To-mesenchymal transition: Examining the functional consequences of plasticity. Breast Cancer Res 2011; 13: 226
10. Yates C. Prostate tumor cell plasticity: A consequence of the microenvironment. Adv Exp Med Biol 2011; 720: 81-90
11. Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 2011; 9: 1608-1620
12. Cano CE, Motoo Y, Iovanna JL. Epithelial-To-mesenchymal transition in pancreatic adenocarcinoma. ScientificWorld J 2010; 10: 1947-1957
13. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D et al. Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33
14. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-To-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2012; 173: 105-112
15. Kang Y. Pro-metastasis function of TGF beta mediated by the Smad pathway. J Cell Biochem 2006; 98: 1380-1390. (Pubitemid 44141845
16. Wakefield LM, Piek E, Bottinger EP. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6: 67-82. (Pubitemid 33640647
17. Baxley SE, Serra R. Inhibiting breast cancer progression by exploiting TGF beta signaling. Curr Drug Targets 2010; 11: 1089-1102
18. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelialmesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010; 15: 169-190
19. Bao J, Zervos AS. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996; 12: 2171-2176. (Pubitemid 26168426
20. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- And IFNg-mediated signaling. Cell 1999; 96: 121-130
21. Li H, Lee T, Avraham HA. Novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 2002; 277: 20965-20973. (Pubitemid 34967407
22. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA et al. Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer 2009; 125: 556-564
23. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747
24. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008; 25: 629-642
25. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268. (Pubitemid 36677560
26. Zavadil J, Bottinger EP. TGF-beta and epithelial-To-mesenchymal transitions. Oncogene 2005; 24: 5764-5774
27. Postigo AA. Opposing functions of ZEB proteins in the regulation of the TGFbeta/ BMP signaling pathway. EMBO J 2003; 22: 2443-2452. (Pubitemid 36604983
28. Joseph MJ, Dangi-Garimella S, Shields MA, Diamond ME, Sun L, Koblinski JE et al. Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. J Cell Biochem 2009; 108: 726-736
29. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E et al. T helper type 1 development of naive CD4 T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 1994; 24: 793-798
30. Xiao BG, Zhang GX, Ma CG, Link H. Transforming growth factor-beta 1 (TGFbeta1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-gamma (IFN-gamma). Clin Exp Immunol 1996; 103: 475-481
31. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-713
32. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172
33. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in Development and disease. Cell 2009; 139: 871-890
34. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011; 27: 347-376
35. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374-383. (Pubitemid 47509716
36. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008; 130: 481-494
37. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110
38. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 253-260
39. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: Interplay between cancer stem cells, embryonic signaling pathways and epithelial-Tomesenchymal transition. Breast Cancer Res 2011; 13: 211
40. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGFbeta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374
41. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: Implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005; 179: 11-23
42. Tian YC, Fraser D, Attisano L, Phillips AO. TGF-beta1-mediated alterations of renal proximal tubular epithelial cell phenotype. Am J Physiol Renal Physiol 2003; 285: F130-F142. (Pubitemid 36818470
43. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE et al. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2004; 64: 4523-4530. (Pubitemid 38856924
44. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999; 112: 4557-4568. (Pubitemid 30034805
45. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005; 16: 1987-2002. (Pubitemid 40471965
46. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 314-323
47. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 70: 968-978
48. Saika S, Ikeda K, Yamanaka O, Sato M, Muragaki Y, Ohnishi Y et al. Transient adenoviral gene transfer of Smad7 prevents injury-induced epithelial-mesenchymal transition of lens epithelium in mice. Lab Invest 2004; 84: 1259-1270. (Pubitemid 40063692
49. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 263-272
50. Yan X, Chen YG. Smad7: Not only a regulator, but also a cross-Talk mediator of TGF-beta signalling. Biochem J 2011; 434: 1-10
51. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012; 31: 5162-5171
52. Cocolakis E, Dai M, Drevet L, Ho J, Haines E, Ali S et al. Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J Biol Chem 2008; 283: 1293-1307
53. Iwamoto T, Oshima K, Seng T, Feng X, Oo ML, Hamaguchi M et al. STAT and SMAD signaling in cancer. Histol Histopathol 2002; 17: 887-895. (Pubitemid 34784672
54. Weng H, Mertens PR, Gressner AM, Dooley S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007; 46: 295-303. (Pubitemid 44959156
55. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736
56. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Canc Metastasis Rev 2012; 31: 469-478
57. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-617. (Pubitemid 128374697
58. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
59. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005
60. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810. (Pubitemid 350035380
61. Blander G, Guarente L. The Sir2 family of protein Deacetylases. Annu Rev Biochem 2004; 73: 417-435. (Pubitemid 39050375
62. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-6618. (Pubitemid 47105506
63. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41: 366-371
64. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009; 15: 4453-4459
65. Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M et al. Function of the SIRT1 protein Deacetylase in cancer. Biotechnol J 2007; 2: 1360-1368. (Pubitemid 350176266
66. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 2011; 71: 4138-4149
67. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
68. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658. (Pubitemid 47187346
69. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845
70. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 264-269
71. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006; 25: 176-185. (Pubitemid 43083679
72. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3: E2020
73. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-323
74. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284: 18210-18217
75. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 6: E28103
76. Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One 7: E34265
77. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S et al. miRNAs regulate SIRT1 expression During mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) 2010; 2: 415-431
78. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011; 20: 187-199
79. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: Genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-244
80. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Chang YG et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-Terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012; 56: 644-657
81. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013; 57: 1055-1067
82. Niyazi M, Niyazi I, Belka C. Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol 2007; 2: 4